Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
May 21, 2020 07:00 ET | Sorrento Therapeutics, Inc.
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...
PRPO logo.png
Continued ICP Orders From Japanese Customers
March 05, 2019 07:40 ET | Precipio, Inc.
NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from...
PRPO logo.png
Precipio ICE COLD-PCR™ Technology Selected by the University of Cincinnati Medical Center for Liquid Biopsy Study
November 27, 2018 09:38 ET | Precipio, Inc.
NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that its ICE COLD-PCR™ (ICP) technology has been selected for a...
PRPO logo.png
Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering
September 20, 2018 07:37 ET | Precipio, Inc.
New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced...
PRPO logo.png
Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance
February 15, 2018 08:38 ET | Precipio, Inc.
NEW HAVEN, Conn., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ:PRPO) announced today its launch of the first lung cancer treatment resistance panel specifically for the critical...